Share This Author
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma
For patients with persistent asthma, the National Asthma Education and Prevention Program recommends the regular use of controller medications to provide long-term control, together with as-needed…
Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind Trial
Montelukast improves morning FEV1 in 6- to 14-year-old children with chronic asthma, and this is the first study of its kind to study children younger than 12 years with asthma using a leukotriene receptor antagonist.
Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
- T. Reiss, P. Chervinsky, R. Dockhorn, S. Shingo, B. Seidenberg, T. B. Edwards
- MedicineArchives of internal medicine
- 8 June 1998
Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period and was generally well tolerated, with an adverse event profile comparable with that of placebo.
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
After 12 weeks of treatment, patients in the montelukast group were more likely to rate their asthma control as better and less likely to require rescue therapy with a beta-agonist during or after exercise challenge.
Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
- S. Dahlén, K. Malmström, A. Szczeklik
- Medicine, PsychologyAmerican journal of respiratory and critical care…
Addition of a leukotriene receptor antagonist such as montelukast improves asthma in aspirin-intolerant patients over and above what can be achieved by glucocorticosteroids.
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
What are minimal important changes for asthma measures in a clinical trial?
- N. Santanello, J. Zhang, B. Seidenberg, T. Reiss, B. Barber
- Medicine, PsychologyThe European respiratory journal
- 1 July 1999
Patients in a randomized, placebo-controlled clinical trial of a leukotriene antagonist experienced less mean improvement from baseline than active-treated patients and younger patients, who reported minimal improvement.
Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
The safety profile of montelukast, an oral leukotriene receptor antagonist, in preschool children with persistent asthma was determined to determine the frequency of asthma attacks, discontinuations from the study because of worsening asthma, need for rescue medication, and the frequencies of adverse effects.
The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis
Montelukast provides significant relief from symptoms of seasonal allergic rhinitis, while also conferring a benefit for asthma, in patients with both allergic Rhinitis and asthma.